Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
- Submitting institution
-
The University of Sheffield
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 318
- Type
- D - Journal article
- DOI
-
10.3310/hta20350
- Title of journal
- Health Technology Assessment
- Article number
- -
- First page
- 1
- Volume
- 20
- Issue
- 35
- ISSN
- 1366-5278
- Open access status
- Out of scope for open access requirements
- Month of publication
- May
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
11
- Research group(s)
-
E - Health Technology Assessment
- Citation count
- 69
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
